• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    China Pharmacovigilance Market

    ID: MRFR/Pharma/49098-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    China Pharmacovigilance Market Research Report By Service Type (Adverse Event Reporting, Risk Assessment, Data Mining, Pharmacovigilance Consulting), By Deployment Mode (Cloud-Based, On-Premise), By Source (Spontaneous Reporting, Literature Reports, Scheduled Reporting) and By End User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    China Pharmacovigilance Market Research Report - Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    China Pharmacovigilance Market Summary

    The China Pharmacovigilance market is poised for substantial growth, with a projected valuation increase from 592.5 million USD in 2024 to 1215 million USD by 2035.

    Key Market Trends & Highlights

    China Pharmacovigilance Key Trends and Highlights

    • The market is expected to grow from 592.5 million USD in 2024 to 1215 million USD by 2035.
    • A compound annual growth rate (CAGR) of 6.75 percent is anticipated from 2025 to 2035.
    • The increasing focus on drug safety and regulatory compliance is driving market expansion.
    • Growing adoption of advanced data analytics due to the need for enhanced patient safety is a major market driver.

    Market Size & Forecast

    2024 Market Size 592.5 (USD Million)
    2035 Market Size 1215 (USD Million)
    CAGR (2025-2035) 6.75%

    Major Players

    Pfizer, Teva Pharmaceutical Industries, Boehringer Ingelheim, Amgen, Merck & Co, Eli Lilly and Company, GlaxoSmithKline, Roche, AstraZeneca, Johnson & Johnson, AbbVie, Sanofi, Novartis, Bristol Myers Squibb

    China Pharmacovigilance Market Trends

    The growing focus on adverse drug reaction monitoring and patient safety is causing major changes in the China Pharmacovigilance Market. The National Medical Products Administration's (NMPA) amended rules reflect the Chinese government's tightening of medication safety regulations in response to the country's rapidly changing healthcare environment. The goal of this stricter regulation is to improve the general caliber of medications available on the market, which in turn fuels the need for strong pharmacovigilance systems. Recent patterns indicate that pharmacovigilance procedures are increasingly incorporating cutting-edge technologies like big data analytics and artificial intelligence.

    Furthermore, cooperation between pharmaceutical firms, medical facilities, and government agencies offers a beneficial path forward, cultivating a culture of proactive risk management and safety evaluation. Overall, the market trends in the China Pharmacovigilance Market show a steady transition towards a more technologically advanced and integrated approach to drug safety, which is in line with international best practices while taking into account the particularities of the Chinese healthcare infrastructure.

    China Pharmacovigilance Market Drivers

    Market Segment Insights

    Get more detailed insights about China Pharmacovigilance Market Research Report - Forecast to 2035

    Regional Insights

    Key Players and Competitive Insights

    The China Pharmacovigilance Market has experienced significant growth and transformation in recent years, shaped by various factors including regulatory advancements, increasing patient awareness, and the rising prevalence of chronic diseases. The competitive landscape is characterized by the presence of both domestic and international players who are increasingly focusing on ensuring drug safety and efficacy through rigorous monitoring processes. Companies within this market not only strive to comply with stringent regulatory frameworks established by the Chinese government but also seek to leverage technological advances to enhance pharmacovigilance activities. 

    This market is essential in supporting the overall healthcare system by ensuring that therapeutic products are continuously assessed for their risk-benefit profiles post-market launch, thereby safeguarding public health.Pfizer is a notable player in the China Pharmacovigilance Market, boasting a robust presence that emphasizes safety and efficacy in its wide range of pharmaceutical products. Its established infrastructure allows for an efficient collection and analysis of safety data, which is crucial in the identification and assessment of adverse drug reactions. 

    Pfizer has also demonstrated significant agility in adapting to the local regulatory landscape, ensuring compliance with government mandates while maintaining high standards of safety in its offerings. The company's strengths lie in its research capabilities and its commitment to innovative solutions that elevate pharmacovigilance practices in China. Furthermore, Pfizer's extensive portfolio across multiple therapeutic areas enables it to have a comprehensive approach to monitoring and managing drug safety.Teva Pharmaceutical Industries holds a commendable position within the China Pharmacovigilance Market, offering a variety of generics and specialty drugs that require diligent safety surveillance. 

    The company's commitment to robust pharmacovigilance practices is evident through its systematic approach to monitoring adverse events associated with its products, ensuring that patients receive safe and effective medications. Teva maintains strong partnerships within the local healthcare system, which enhances its market presence and amplifies its pharmacovigilance efforts. The company's focus on key products, including both generics and branded medications, necessitates a well-orchestrated strategy for risk assessment and management.

    Additionally, Teva has made strides in strengthening its operations in China through targeted mergers and acquisitions aimed at enhancing its product offerings and expanding its reach within the market, further solidifying its role in ensuring drug safety in the region.

    Key Companies in the China Pharmacovigilance Market market include

    Industry Developments

    In recent months, the China Pharmacovigilance Market has seen significant developments, particularly with major companies such as Pfizer, Merck and Co, and Roche actively expanding their pharmacovigilance practices to enhance patient safety amid increasing regulatory requirements. In October 2023, Merck and Co announced a strategic initiative to strengthen its drug safety assessments in China in response to the government's push for more rigorous clinical trial regulations. Furthermore, in September 2023, Johnson and Johnson expanded its existing partnership with local organizations focusing on adverse event reporting and risk management, reflecting the growing emphasis on regulatory compliance in the region.

    Noteworthy in the last couple of years, in March 2022, AstraZeneca reported a 15% increase in market valuation due to its extensive pharmacovigilance framework that aligns with China's national standards. Meanwhile, Teva Pharmaceutical Industries has been investing heavily in its data analytics capabilities to improve its pharmacovigilance operations in China, recognizing the rising demand for transparency in drug safety data. The continuous growth in China’s pharmaceutical sector, characterized by both domestic and international investments, showcases an active and evolving pharmacovigilance environment, aiming to ensure patient safety and uphold public health standards.

    Market Segmentation

    Outlook

    • Pharmaceutical Companies
    • Biotechnology Companies
    • Contract Research Organizations

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 558.75(USD Million)
    MARKET SIZE 2024 592.5(USD Million)
    MARKET SIZE 2035 1215.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 6.746% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Pfizer, Teva Pharmaceutical Industries, Boehringer Ingelheim, Amgen, Merck & Co, Eli Lilly and Company, GlaxoSmithKline, Roche, AstraZeneca, Johnson & Johnson, AbbVie, Sanofi, Novartis, Bristol Myers Squibb
    SEGMENTS COVERED Service Type, Deployment Mode, Source, End User
    KEY MARKET OPPORTUNITIES Growing regulatory compliance requirements, Increased demand for real-time monitoring, Expansion of biopharmaceutical industry, Integration of AI technology, Rising awareness of patient safety
    KEY MARKET DYNAMICS regulatory compliance requirements, increasing drug safety concerns, technological advancements in data analysis, rising adverse event reporting, growing demand for collaborative platforms
    COUNTRIES COVERED China

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the expected market size of the China Pharmacovigilance Market in 2024?

    The China Pharmacovigilance Market is expected to be valued at 592.5 million USD in 2024.

    What is the projected market size for the China Pharmacovigilance Market by 2035?

    By 2035, the China Pharmacovigilance Market is anticipated to reach a valuation of 1215.0 million USD.

    What is the expected CAGR for the China Pharmacovigilance Market from 2025 to 2035?

    The expected compound annual growth rate for the China Pharmacovigilance Market from 2025 to 2035 is 6.746%.

    Which service type segment dominates the China Pharmacovigilance Market?

    Adverse Event Reporting currently dominates the market, valued at 150.0 million USD in 2024.

    What is the projected market value for Risk Assessment in 2035?

    The Risk Assessment segment is projected to reach a value of 240.0 million USD by 2035.

    How much is the Data Mining segment expected to be valued at in 2024?

    The Data Mining segment is expected to be valued at 80.0 million USD in 2024.

    What is the expected valuation for Pharmacovigilance Consulting in 2035?

    By 2035, the Pharmacovigilance Consulting segment is expected to be valued at 515.0 million USD.

    Who are the major players in the China Pharmacovigilance Market?

    Key players include Pfizer, Merck & Co, Johnson & Johnson, and Roche among others.

    What growth opportunities are anticipated in the China Pharmacovigilance Market?

    The growing importance of drug safety and regulatory compliance provides significant growth opportunities.

    What challenges is the China Pharmacovigilance Market currently facing?

    Challenges include the need for advanced technologies and skilled personnel to manage complex data effectively.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. China Pharmacovigilance Market, BY Service Type (USD Million)
    45. Adverse Event Reporting
    46. Risk Assessment
    47. Data Mining
    48. Pharmacovigilance Consulting
    49. China Pharmacovigilance Market, BY Deployment Mode (USD Million)
    50. Cloud-Based
    51. On-Premise
    52. China Pharmacovigilance Market, BY Source (USD Million)
    53. Spontaneous Reporting
    54. Literature Reports
    55. Scheduled Reporting
    56. China Pharmacovigilance Market, BY End User (USD Million)
    57. Pharmaceutical Companies
    58. Biotechnology Companies
    59. Contract Research Organizations
    60. Competitive Landscape
    61. Overview
    62. Competitive Analysis
    63. Market share Analysis
    64. Major Growth Strategy in the Pharmacovigilance Market
    65. Competitive Benchmarking
    66. Leading Players in Terms of Number of Developments in the Pharmacovigilance Market
    67. Key developments and growth strategies
    68. New Product Launch/Service Deployment
    69. Merger & Acquisitions
    70. Joint Ventures
    71. Major Players Financial Matrix
    72. Sales and Operating Income
    73. Major Players R&D Expenditure. 2023
    74. Company Profiles
    75. Pfizer
    76. Financial Overview
    77. Products Offered
    78. Key Developments
    79. SWOT Analysis
    80. Key Strategies
    81. Teva Pharmaceutical Industries
    82. Financial Overview
    83. Products Offered
    84. Key Developments
    85. SWOT Analysis
    86. Key Strategies
    87. Boehringer Ingelheim
    88. Financial Overview
    89. Products Offered
    90. Key Developments
    91. SWOT Analysis
    92. Key Strategies
    93. Amgen
    94. Financial Overview
    95. Products Offered
    96. Key Developments
    97. SWOT Analysis
    98. Key Strategies
    99. Merck & Co
    100. Financial Overview
    101. Products Offered
    102. Key Developments
    103. SWOT Analysis
    104. Key Strategies
    105. Eli Lilly and Company
    106. Financial Overview
    107. Products Offered
    108. Key Developments
    109. SWOT Analysis
    110. Key Strategies
    111. GlaxoSmithKline
    112. Financial Overview
    113. Products Offered
    114. Key Developments
    115. SWOT Analysis
    116. Key Strategies
    117. Roche
    118. Financial Overview
    119. Products Offered
    120. Key Developments
    121. SWOT Analysis
    122. Key Strategies
    123. AstraZeneca
    124. Financial Overview
    125. Products Offered
    126. Key Developments
    127. SWOT Analysis
    128. Key Strategies
    129. Johnson & Johnson
    130. Financial Overview
    131. Products Offered
    132. Key Developments
    133. SWOT Analysis
    134. Key Strategies
    135. AbbVie
    136. Financial Overview
    137. Products Offered
    138. Key Developments
    139. SWOT Analysis
    140. Key Strategies
    141. Sanofi
    142. Financial Overview
    143. Products Offered
    144. Key Developments
    145. SWOT Analysis
    146. Key Strategies
    147. Novartis
    148. Financial Overview
    149. Products Offered
    150. Key Developments
    151. SWOT Analysis
    152. Key Strategies
    153. Bristol Myers Squibb
    154. Financial Overview
    155. Products Offered
    156. Key Developments
    157. SWOT Analysis
    158. Key Strategies
    159. References
    160. Related Reports
    161. China Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY SERVICE TYPE, 2019-2035 (USD Billions)
    162. China Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY DEPLOYMENT MODE, 2019-2035 (USD Billions)
    163. China Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY SOURCE, 2019-2035 (USD Billions)
    164. China Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    165. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    166. ACQUISITION/PARTNERSHIP
    167. MARKET SYNOPSIS
    168. CHINA PHARMACOVIGILANCE MARKET ANALYSIS BY SERVICE TYPE
    169. CHINA PHARMACOVIGILANCE MARKET ANALYSIS BY DEPLOYMENT MODE
    170. CHINA PHARMACOVIGILANCE MARKET ANALYSIS BY SOURCE
    171. CHINA PHARMACOVIGILANCE MARKET ANALYSIS BY END USER
    172. KEY BUYING CRITERIA OF PHARMACOVIGILANCE MARKET
    173. RESEARCH PROCESS OF MRFR
    174. DRO ANALYSIS OF PHARMACOVIGILANCE MARKET
    175. DRIVERS IMPACT ANALYSIS: PHARMACOVIGILANCE MARKET
    176. RESTRAINTS IMPACT ANALYSIS: PHARMACOVIGILANCE MARKET
    177. SUPPLY / VALUE CHAIN: PHARMACOVIGILANCE MARKET
    178. PHARMACOVIGILANCE MARKET, BY SERVICE TYPE, 2025 (% SHARE)
    179. PHARMACOVIGILANCE MARKET, BY SERVICE TYPE, 2019 TO 2035 (USD Billions)
    180. PHARMACOVIGILANCE MARKET, BY DEPLOYMENT MODE, 2025 (% SHARE)
    181. PHARMACOVIGILANCE MARKET, BY DEPLOYMENT MODE, 2019 TO 2035 (USD Billions)
    182. PHARMACOVIGILANCE MARKET, BY SOURCE, 2025 (% SHARE)
    183. PHARMACOVIGILANCE MARKET, BY SOURCE, 2019 TO 2035 (USD Billions)
    184. PHARMACOVIGILANCE MARKET, BY END USER, 2025 (% SHARE)
    185. PHARMACOVIGILANCE MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    186. BENCHMARKING OF MAJOR COMPETITORS

    China Pharmacovigilance Market Segmentation

     

     

     

    • Pharmacovigilance Market By Service Type (USD Million, 2019-2035)

      • Adverse Event Reporting
      • Risk Assessment
      • Data Mining
      • Pharmacovigilance Consulting

     

    • Pharmacovigilance Market By Deployment Mode (USD Million, 2019-2035)

      • Cloud-Based
      • On-Premise

     

    • Pharmacovigilance Market By Source (USD Million, 2019-2035)

      • Spontaneous Reporting
      • Literature Reports
      • Scheduled Reporting

     

    • Pharmacovigilance Market By End User (USD Million, 2019-2035)

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Contract Research Organizations

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials